Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 19, Pages 8639-8657Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b00611
Keywords
-
Categories
Funding
- National Institute on Drug Abuse [DA009158, DA007215]
Ask authors/readers for more resources
The synthesis of potent metabolically stable endocannabinoids is challenging. Here we report a chiral arachidonoyl ethanolamide (AEA) analogue, namely, (13S,1'R)-dimethylanandamide (AMG315, 3a), a high affinity ligand for the CB1 receptor (K-i of 7.8 +/- 1.4 nM) that behaves as a potent CB1 agonist in vitro (EC50 = 0.6 +/- 0.2 nM). (13S,1'R)-dimethylanandamide is the first potent AEA analogue with significant stability for all endocannabinoid hydrolyzing enzymes as well as the oxidative enzymes COX-2. When tested in vivo using the CFA-induced inflammatory pain model, 3a behaved as a more potent analgesic when compared to endogenous AEA or its hydrolytically stable analogue AM356. This novel analogue will serve as a very useful endocannabinoid probe.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available